OS Therapies announced positive interim three-year overall survival data for its OST-HER2 bone cancer treatment, showing a statistically significant improvement over historical controls. This positive clinical trial update, coupled with securing VAT refunds for a Phase 3 expansion, suggests a strong potential for future regulatory approvals and market entry.
OS Therapies (OSTX) reported highly encouraging interim Phase 2b data for its OST-HER2 therapy, demonstrating a 71.2% overall survival rate at three years compared to a 45.8% historical control. This statistically significant benefit is a major positive for the company, indicating strong therapeutic potential for metastatic osteosarcoma. Furthermore, the company secured $3.15 million in VAT refunds and expects an additional $7.2 million, which will fund a crucial confirmatory Phase 3 trial in the U.K. This Phase 3 trial is essential for pursuing accelerated approval in the U.S. and conditional marketing authorizations in other key regions. While the stock was down slightly on the day of publication, likely due to broader market movements or profit-taking, the long-term implications are significantly positive, offering a clear path towards commercialization and addressing a critical unmet medical need. The key opportunity for traders lies in the potential for future regulatory milestones and market expansion.